View Item 

Show simple item record

Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine‐based therapy with or without bevacizumab
dc.contributor.authorPant, Shubhamen_US
dc.contributor.authorMartin, Ludmila K.en_US
dc.contributor.authorGeyer, Susanen_US
dc.contributor.authorWei, Laien_US
dc.contributor.authorVan Loon, Katherineen_US
dc.contributor.authorSommovilla, Nillien_US
dc.contributor.authorZalupski, Marken_US
dc.contributor.authorIyer, Renukaen_US
dc.contributor.authorFogelman, Daviden_US
dc.contributor.authorKo, Andrew H.en_US
dc.contributor.authorBekaii‐saab, Taniosen_US
dc.date.accessioned2014-06-04T14:57:06Z
dc.date.availableWITHHELD_13_MONTHSen_US
dc.date.available2014-06-04T14:57:06Z
dc.date.issued2014-06-15en_US
dc.identifier.citationPant, Shubham; Martin, Ludmila K.; Geyer, Susan; Wei, Lai; Van Loon, Katherine; Sommovilla, Nilli; Zalupski, Mark; Iyer, Renuka; Fogelman, David; Ko, Andrew H.; Bekaii‐saab, Tanios (2014). "Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabineâ based therapy with or without bevacizumab." Cancer 120(12): 1780-1786.en_US
dc.identifier.issn0008-543Xen_US
dc.identifier.issn1097-0142en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/107373
dc.publisherJohn Wiley & Sonsen_US
dc.subject.otherAlbuminen_US
dc.subject.otherBevacizumaben_US
dc.subject.otherPancreatic Canceren_US
dc.subject.otherPredictive Biomarkeren_US
dc.titleBaseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine‐based therapy with or without bevacizumaben_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/107373/1/cncr28648.pdf
dc.identifier.doi10.1002/cncr.28648en_US
dc.identifier.sourceCanceren_US
dc.identifier.citedreferenceKo AH, Dito E, Schillinger B, et al. A phase II study evaluating bevacizumab in combination with fixed‐dose rate gemcitabine and low‐dose cisplatin for metastatic pancreatic cancer: is an anti‐VEGF strategy still applicable? Invest New Drugs. 2008; 26: 463 ‐ 471.en_US
dc.identifier.citedreferenceJemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277 ‐ 300.en_US
dc.identifier.citedreferenceBurris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5‐fluorouracil. Eur J Cancer. 1997; 33 (suppl 1 ): S18 ‐ S22.en_US
dc.identifier.citedreferenceConroy T, Desseigne F, Ychou M, et al; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364: 1817 ‐ 1825.en_US
dc.identifier.citedreferenceVon Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab‐paclitaxel plus gemcitabine. N Engl J Med. 2013; 369: 1691 ‐ 1703.en_US
dc.identifier.citedreferenceGenentech. Avastin Prescribing Information. South San Francisco, CA: Genentech Inc; 2013.en_US
dc.identifier.citedreferenceBuchler P, Reber HA, Ullrich A, et al. Pancreatic cancer growth is inhibited by blockade of VEGF‐RII. Surgery. 2003; 134: 772 ‐ 782.en_US
dc.identifier.citedreferenceBaker CH, Solorzano CC, Fidler IJ. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res. 2002; 62: 1996 ‐ 2003.en_US
dc.identifier.citedreferenceBruns CJ, Shrader M, Harbison MT, et al. Effect of the vascular endothelial growth factor receptor‐2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer. 2002; 102: 101 ‐ 108.en_US
dc.identifier.citedreferenceVan Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009; 27: 2231 ‐ 2237.en_US
dc.identifier.citedreferenceKindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010; 28: 3617 ‐ 3622.en_US
dc.identifier.citedreferenceKindler HL, Ioka T, Richel DJ, et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double‐blind randomised phase 3 study. Lancet Oncol. 2011; 12: 256 ‐ 262.en_US
dc.identifier.citedreferenceVan Cutsem E, Jayson G, Dive C, et al. Analysis of blood plasma factors in the AVITA Phase III randomized study of bevacizumab (bev) with gemcitabine‐erlotinib (GE) in patients (pts) with metastatic pancreatic cancer (mPC) [abstract]. Eur J Cancer. 2011; 47 (suppl 1 ): S95 – S96.en_US
dc.identifier.citedreferenceGaudreault J, Lieberman G, Kabbinavar E, et al. Pharmacokinetics of bevacizumab (BV) in colorectal cancer (CRC). Clin Pharmacol Ther. 2001; 69: 25.en_US
dc.identifier.citedreferenceLu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol. 2008; 62: 779 ‐ 786.en_US
dc.identifier.citedreferenceZondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother. 2004; 38: 1258 ‐ 1264.en_US
dc.identifier.citedreferenceMartin LK, Li X, Kleiber B, et al. VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi‐institutional phase II study of bevacizumab, gemcitabine, and infusional 5‐fluorouracil in patients with APCA. Ann Oncol. 2012; 23: 2812 ‐ 2820.en_US
dc.identifier.citedreferenceKo AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2006; 24: 379 ‐ 385.en_US
dc.identifier.citedreferenceJavle M, Yu J, Garrett C, et al. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. Br J Cancer. 2009; 100: 1842 ‐ 1845.en_US
dc.identifier.citedreferenceFogelman D, Jafari M, Varadhachary GR, et al. Bevacizumab plus gemcitabine and oxaliplatin as first‐line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol. 2011; 68: 1431 ‐ 1438.en_US
dc.identifier.citedreferenceHill ME, Li X, Kim S, et al. A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas. Cancer Chemother Pharmacol. 2011; 67: 511 ‐ 517.en_US
dc.identifier.citedreferenceKo AH, Espinoza AM, Jones KA, et al. Optimizing the administration of fixed‐dose rate gemcitabine plus capecitabine using an alternating‐week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012; 35: 411 ‐ 417.en_US
dc.identifier.citedreferenceHosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons; 2000.en_US
dc.identifier.citedreferenceTherneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer‐Verlag; 2000.en_US
dc.identifier.citedreferenceTherneau GA, Grambsch PM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994; 81: 515 ‐ 526.en_US
dc.identifier.citedreferenceKaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457 ‐ 481.en_US
dc.identifier.citedreferenceHarrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biometrika. 1982; 69: 553 ‐ 566.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr28648.pdf
Size:
215.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.